Developing a prognostic model for localized Ewing XXXX : A single institutional experience of 224 cases treated with uniform chemotherapy protocol.

@entity1 @entity5 @entity3012
BACKGROUND: Data on @entity1 with localized Ewing @entity5 (ESFT) who have received a uniform chemotherapy protocol are minimal. METHODS: This is a single institutional review of @entity1 with ESFT treated between June 2003 and November 2011. RESULTS: 224/374 (60%) @entity1 with ESFT presented with localized disease; median age was 15 years (range: 0.1-55). Ninety-nine @entity1 underwent surgery of which 50 received adjuvant radiotherapy; 80 @entity1 received radical radiotherapy following neoadjuvant chemotherapy. At median follow-up of 40.2 months (range: 1.3-129), 5-year EFS, @entity3012 , and local-control-rate, were 36.8        3.6%, 52.4        4.3%, and 63        4.3%, respectively. In multivariate analysis, @entity5 diameter >8   cm (P   =   0.03), symptom duration >4 months (P   =   0.04), and WBC >11   *   10(9) /L (P   =   0.003) predicted inferior EFS; spine/abdomino-pelvic primary (P   =   0.009) and WBC >11   *   10(9) /L (P   =   0.003) predicted inferior @entity3012 . @entity5 size >8   cm (P   =   0.03) and radical radiotherapy as local treatment (P   =   0.01) predicted inferior local-control-rate. CONCLUSION: Prognostic hazard models for EFS and @entity3012 based on significant prognostic factors suggested that @entity1 with combination of ESFT of spine/abdomino-pelvic region and baseline WBC >11   *   10(9) /L had inferior @entity3012 (hazard ratio 4.44, P   <   0.001) while @entity1 with combination of ESFT with symptom duration >4 months, @entity5 diameter >8   m and baseline WBC >11   *   10(9) /L had inferior EFS (hazard ratio 3.89, P   =   0.002). J. Surg. Oncol.    2014 Wiley Periodicals, Inc.
